Starpharma’s headquarters / Baker IDI Institute / Starpharma Baker IDI Building / /
IndustryTerm
dendrimer technology / dendrimer-conjugate technology / pharmaceutical / dendrimer products / pharmaceutical uses / tumour site / drug delivery applications / dendrimer product / pharmaceuticals / active pharmaceutical ingredient / physico-chemical properties / chemical processes / breakdown products / synthesised using standard chemical processes / /
MarketIndex
ASX 300 / /
MedicalCondition
solid tumours / HIV / genital herpes / bacterial vaginosis / Acid-Labile Linker Newly forming tumors / breast cancer / tumor / cancer / tumour / closely related cancer / sexually transmitted infections / blood clot / tumours / /
MedicalTreatment
chemotherapy / dendrimer / dendrimers / /
Movie
HALF-LIFE / /
Organization
National Institute of Health / Baker IDI Institute / /
Person
Malcolm McColl / Paul Barrett / / /
Position
VP Business Development paul.barrett@starpharma.com / market leader / VP Business Development malcolm.mccoll@starpharma.com / leader in the development / c e o / /
Product
Paclitaxel / Taxotere / /
Technology
dendrimer technology / API / MRI / drug delivery / chemotherapy / dendrimer-conjugate technology / The dendrimer technology / drug development / /
CONTROLLING SOLUBILITY, HALF-LIFE, TOXICITY AND TARGETING The use of macromolecule conjugates to enhance the performance of pharmaceuticals is currently an area of intense research for both small molecules and biological